MDMA stories

Sep 18, 2026

Compass Pathways prepares psychedelic drug launch following J&J's ketamine strategy

Compass Pathways executives revealed plans to model their upcoming psychedelic treatment launch after Johnson & Johnson's strategy for Spravato, the ketamine nasal spray, as the FDA considers approval. The move comes as psychedelic therapeutics face a critical juncture following Lykos' failed MDMA therapy approval in 2024.

Sep 18, 20262 sources

Sep 4, 2026

New Zealand approves MDMA for treatment of severe PTSD

New Zealand's pharmaceutical regulator has approved two psychiatrists to prescribe pharmaceutical-grade MDMA to patients suffering from severe post-traumatic stress disorder, marking a significant shift in mental health treatment policy.

Sep 4, 20263 sources

Top claims

▪Eli Lilly acquired AtaiBeckley for $3.8 billion in the summer of 2026, representing a major pharmaceutical acquisition in the psychedelic therapeutics sector.
▪COMP360 succeeded in two Phase 3 clinical trials for treatment-resistant depression, demonstrating durability and clinical efficacy.
▪AbbVie acquired Gilgamesh Pharmaceuticals' depression drug bretisilocin for $1.2 billion, while Otsuka Pharmaceutical acquired Mindset Pharma in 2023.

Subtopics

Mental Health & Wellbeing2 Psychedelic policy & regulation2 Depression1 Drug Approval and Clinical Trials1 Drug Policy, Pricing & Approval1 Ketamine1 Neurodiversity & Cognitive Function1 Pharma1 Psychedelic clinical research & trials1 Psychedelic renaissance1 Psychedelic-assisted therapy1 Psychedelics for PTSD1 Trauma & PTSD1

Related timelines